Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

320
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
320
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

159
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
159
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

119
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
119

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to: "The Future of Clinical Pharmacology: The Right Medicine at the Right Dose for Each Patient".

Clinical pharmacology and therapeutics·2026
Same author

Simulation Framework to Investigate Efficacy and Ocular Safety of Belantamab Mafodotin Combinations in Relapsed/Refractory Multiple Myeloma.

CPT: pharmacometrics & systems pharmacology·2026
Same author

The Future of Clinical Translational Pharmacology.

Clinical pharmacology and therapeutics·2026
Same author

Impact of Event-Related Treatment Modifications in Exposure-Response Analyses of Repeated Time-to-Event Data.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Causal Directed Acyclic Graphs to Mitigate Confounding Bias in Exposure-Response Analyses.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Development and Use of a Population Pharmacokinetic Model for Characterizing the Pharmacokinetics of Vonoprazan in Pediatric Patients.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

A Narrative Review of Artificial Intelligence for Drug Repurposing: Lessons From COVID-19 and Oncology (2020-2025).

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Butorphanol Pharmacokinetics Across Species: Meta-Analysis Integrating Allometric Scaling and Minimal Physiologically Based Pharmacokinetic Modeling.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Accelerating Subcutaneous Drug Development: A Mechanistic Absorption Model for the Open Systems Pharmacology Framework.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Automated Pharmacometric Model Development by Leveraging Low-Dimensional Neural ODEs and LASSO Regression.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Population Pharmacokinetics and Pharmacodynamics of Paracetamol in Malaysian Patients With Plasmodium knowlesi Malaria.

CPT: pharmacometrics & systems pharmacology·2026
See all related articles

Related Experiment Video

Updated: May 26, 2025

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.1K

Tutorial on Conditional Simulations With a Tumor Size-Overall Survival Model to Support Oncology Drug Development.

Sebastiaan C Goulooze1, Morris Muliaditan1, Richard C Franzese2

  • 1LAP&P Consultants, Leiden, the Netherlands.

CPT: Pharmacometrics & Systems Pharmacology
|February 22, 2025
PubMed
Summary
This summary is machine-generated.

This tutorial explains how tumor size (TS)-overall survival (OS) models and conditional simulations can support oncology drug development decisions using early efficacy data. These methods enable prediction of long-term outcomes from interim study results.

Keywords:
methodologymodel‐based drug developmentoncologypopulation pharmacodynamicssimulationsurrogate endpointsurvival analysistumors

More Related Videos

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
12:41

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Published on: December 23, 2022

4.7K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

204

Related Experiment Videos

Last Updated: May 26, 2025

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.1K
Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
12:41

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Published on: December 23, 2022

4.7K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

204

Area of Science:

  • Oncology
  • Biostatistics
  • Drug Development

Background:

  • Overall survival (OS) is the gold standard for oncology drug approval, but initial data are often limited.
  • Early drug development decisions rely on surrogate endpoints like objective response rate and progression-free survival.
  • Tumor size (TS) data, collected early in clinical trials, can be leveraged to predict longer-term OS.

Purpose of the Study:

  • To provide a comprehensive tutorial on using Tumor Size-Overall Survival (TS-OS) models with conditional simulations for oncology drug development.
  • To demonstrate how to support decision-making by predicting long-term OS from early efficacy and TS data.
  • To guide researchers in selecting, applying, and interpreting TS-OS models and simulations for ongoing studies.

Main Methods:

  • Utilizing treatment-agnostic TS-OS link functions to connect early tumor size measurements with predicted OS.
  • Applying conditional simulations (Bayesian forecasting) to ongoing studies, using interim TS and OS data.
  • Detailing the steps for model selection, data application, simulation execution, output generation, and interpretation.

Main Results:

  • TS-OS models offer a framework to forecast potential late-stage success based on early efficacy readouts.
  • Conditional simulations provide a method to estimate long-term OS outcomes for ongoing oncology trials.
  • The tutorial outlines practical steps for implementing these advanced statistical methods in drug development.

Conclusions:

  • Conditional simulations with TS-OS models enhance informed decision-making in oncology drug development.
  • Leveraging early TS and OS data through these models can optimize resource allocation and trial strategies.
  • Accurate interpretation and communication of simulation outputs are crucial for effective decision support.